Compare Fox Corp Class B (FOX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Johnson & Johnson — how do they compare? Fox Corp Class B trades at $55.42 (market cap $24.58B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 25.5× Fox Corp Class B's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| FOX | JNJ | |
|---|---|---|
Market Cap | $24.58B | $626.09B |
Sector | Media | Health |
52-Week High | $67.76 | $267.24 |
52-Week Low | $44.39 | $172.78 |
Enterprise Value | $27.94B | $654.37B |
Dividend Yield | 1.05% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX Corp trades at $55.99, down 0.6% with bullish technical signals and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.79 EPS, beating expectations by 24%, with revenue growth accelerating to $16.3B in 2025. Analyst sentiment remains mixed with 43% buy ratings, while technical indicators show support at $54-55 levels with moving averages trending upward.
Outlook remains positive with digital growth momentum from Tubi and FOX One driving advertising revenue. Key risks include advertising market volatility and competitive pressures. The stock presents value opportunity with reasonable P/E of 14.4x and strong cash flow generation, though investors should monitor Q3 2026 earnings delivery against $2 EPS expectations.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
